Hepatitis C News

In a short-term analysis, researchers found that survival rates improved among patients who underwent liver transplant for chronic hepatitis C after direct-acting antiviral approvals.

New findings suggest that sharing paraphernalia used to cook and prepare injection drugs does not directly lead to transmission of hepatitis C virus.

Direct-acting antiviral use resulted in high rates of sustained virologic response and were safely tolerated in patients with chronic hepatitis C and mixed cryoglobulinemia, according to a recently published study. Researchers observed that most patients did not have a complete clinical or immunological response, however, suggesting a delayed response.

Researchers at West Virginia University are leading a new, federally funded project designed to prevent outbreaks of HIV, hepatitis C and other opioid-related infections through enhanced screening, prevention and treatment efforts, according to a press release.

Health Canada approved Gilead’s Vosevi for treating patients with chronic hepatitis C with genotypes 1 through 6 previously treated with an NS5A inhibitor-containing regimen, or with genotypes 1 through 4 previously treated with sofosbuvir-containing regimen without an NS5A inhibitor, according to a press release.

Health Canada approved AbbVie’s Maviret for treating adults with chronic hepatitis C for all genotypes, according to a press release. Maviret is designated for patients without cirrhosis and who are new to treatment.

Health risk behaviors, such as alcohol use, cigarette smoking and unhealthy diets, contributed equally toward mortality risk for patients with chronic hepatitis C as the infection itself, according to a recently published study.

In this guest commentary, Thelma King Thiel, RN, BA, former CEO of both the American Liver Foundation and the Hepatitis Foundation International, discusses prevention of hepatitis through education . After losing her son to biliary atresia, Theil focused on training health care providers about liver health. She recently founded the Liver Health Initiative to continue to fill the knowledge gap that exists about liver health.

Citizens of indigenous nations are up to 10 times more likely to have hepatitis B or hepatitis C than the general population in their respective countries, according to a press release on meta-analysis data presented at the World Indigenous Peoples’ Conference on Viral Hepatitis in Anchorage, Alaska.

Nearly half of the Cherokee Nation American Indian population received screening for hepatitis C and approximately one-quarter of those with the infection are cured, according to a press release from the World Indigenous People’s Conference on Viral Hepatitis in Anchorage, Alaska, which coincides with the International Day of the World’s Indigenous Peoples on Aug. 9.